Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 48.63% is 182% above its 5-year average of 17.27%, around the middle of its 5-year range (-27.08%–112.05%).
56.73% above its 12-month average of 31.03%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2026 (2026-06-30): 21.68%.
GROSS MARGIN
48.63%
GROSS MARGIN AVG TTM
31.03%
GROSS MARGIN AVG 3Y
25.41%
GROSS MARGIN AVG 5Y
17.27%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+56.73%
CURRENT VS 3Y AVG
+91.38%
CURRENT VS 5Y AVG
+181.63%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.76%
median of 562 covered companies
CURRENT VS SECTOR MEDIAN
+13.73%
vs the sector median at left
Intelligent Bio Solutions Inc.
Market Cap
$5.57M
Gross Margin
48.63%
TTM Avg
31.03%
3Y Avg
25.41%
5Y Avg
17.27%
Market Cap
$5.63M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.82M
Gross Margin
-1.29%
TTM Avg
-3.77%
3Y Avg
16.02%
5Y Avg
20.70%
Market Cap
$5.40M
Gross Margin
77.68%
TTM Avg
77.66%
3Y Avg
77.69%
5Y Avg
77.69%
Market Cap
$6.04M
Gross Margin
100.00%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
83.33%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Intelligent Bio Solutions Inc. (INBS) | $5.57M | 48.63% | 31.03% | 25.41% | 17.27% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | 0.00% | 0.00% | 0.00% | 0.00% |
| Alzamend Neuro Inc (ALZN)vs › | $5.33M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lunai Bioworks Inc. (LNAI)vs › | $5.35M | 0.00% | 0.00% | 0.00% | 0.00% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.82M | -1.29% | -3.77% | 16.02% | 20.70% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.40M | 77.68% | 77.66% | 77.69% | 77.69% |
| Imunon, Inc. (IMNN)vs › | $5.21M | 0.00% | 0.00% | 25.00% | 50.00% |
| Lucyd, Inc (LUCY)vs › | $5.92M | 22.79% | 17.23% | 3.90% | 1.13% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.04M | 100.00% | 100.00% | 100.00% | 83.33% |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.36M | 0.00% | 0.00% | 0.00% | 0.00% |
Gross Margin
48.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 21.68% |
| 2026-03-31 | 23.09% |
| 2025-12-31 | 51.27% |
| 2025-09-30 | 19.33% |
| 2025-06-30 | 39.77% |
| 2025-03-31 | 5.40% |
| 2024-12-31 | 36.73% |
| 2024-09-30 | 5.32% |
| 2024-06-30 | 112.05% |
| 2024-03-31 | 21.67% |
| 2023-12-31 | 26.08% |
| 2023-09-30 | 29.18% |
| 2023-06-30 | -27.08% |
| 2023-03-31 | 7.23% |
| 2022-12-31 | 68.42% |
| 2022-09-30 | 0.00% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 100.00% |
| 2021-03-31 | 100.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 100.00% |
| 2020-06-30 | 100.00% |
| 2020-03-31 | 100.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 100.00% |
